Search

Displaying results 811 - 820 of 4692 in total
  1. Drug

    Tenocyclidine

    go.drugbank.com/drugs/DB01520
    IllicitInvestigational

    Tenocyclidine (TCP, thienyl cyclohexylpiperidine) is a dissociative anesthetic drug with stimulant and hallucinogenic effects. It is more potent than phencyclidine and hence, this drug was classified under the schedule 1 in 1970.

  2. Drug

    Tilactase

    go.drugbank.com/drugs/DB13761
    ApprovedInvestigational

    [A32591] It is considered by the WHO as part of the International Nonpropietary Names for Pharmaceutical Substances.[L2338] … [A27172] The beta-D-galactosidase us a large monomeric multi-domain enzyme of 985 residues that presents a catalytic (alpha/beta)8-barrel domain.

    Products: LACDIGEST 2250 U CIGNEME TABLETI, 100 TABLET, LACDIGEST 2250 U CIGNEME TABLETI, 50 TABLET
  3. Drug

    Candoxatril

    go.drugbank.com/drugs/DB00616
    Experimental

    Candoxatril is the orally-active prodrug of candoxatrilat (UK-73967), a potent neutral endopeptidase (NEP) inhibitor.

  4. Drug

    Insulin icodec

    go.drugbank.com/drugs/DB16693
    ApprovedInvestigational

    [L50758,A263818] Insulin icodec was approved by Health Canada in March 2024 for the treatment of adult patients with type 1 or 2 diabetes mellitus,[L50758] and was subsequently approved by the EMA in … [L51078] In July 2024, the US FDA rejected the approval of insulin icodec, citing concerns regarding hypoglycemia and the indication being sought for type 1 diabetes mellitus.

  5. Drug

    Lacosamide

    go.drugbank.com/drugs/DB06218
    ApprovedInvestigational

    [A262681] Lacosamide was first approved by the European Commission in August 2008 and was later approved by the FDA in October 2008. … [A262681] It was granted approval by Health Canada in September 2010.[L49206]

  6. Drug

    Lisdexamfetamine

    go.drugbank.com/drugs/DB01255
    ApprovedInvestigational

    [A2230] Lisdexamfetamine is the first chemically formulated prodrug stimulant [A40246] and was first approved by the FDA in April 2008.[A2230] It was also approved by Health Canada in February 2009. … [L48285] Lisdexamfetamine works to treat attention deficit hyperactivity disorder and binge eating disorder [A2230] by blocking dopamine and norepinephrine reuptake and increasing their levels in the extraneuronal

  7. Drug

    Umbralisib

    go.drugbank.com/drugs/DB14989
    ApprovedInvestigationalWithdrawn

    [A229363] Follicular lymphoma is also treated with rituximab and other chemotherapeutic agents, but may show similar progression. … It was marketed as Ukoniq by TG Therapeutics and has been approved for the treatment of relapsing and refractory marginal cell lymphoma and follicular lymphoma in adults.

  8. Drug

    Pegzilarginase

    go.drugbank.com/drugs/DB14780
    Approved

    [L56053] By substituting the native manganese cofactor with cobalt to enhance catalytic activity, this agent effectively degrades elevated plasma arginine into ornithine and urea, thereby mitigating the

  9. Drug

    Prademagene zamikeracel

    go.drugbank.com/drugs/DB17895
    ApprovedInvestigational

    [L53013] It was granted an Orphan Drug designation by the EMA.[A273833] … [L53008] Prademagene zamikeracel was first approved by the FDA on April 29, 2025, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a skin disorder associated with excessive blistering

  10. Drug

    Nonivamide

    go.drugbank.com/drugs/DB11324
    Approved

    It is naturally found in chili peppers but manufactured to produce a synthetic form for various pharmacologic preparations [L2641].